β-d-Ribofuranose as a Core with a Phosphodiester Moiety as the Enzyme Recognition Site for Codrug Development

Authors:
Open Access
Publisher website
Google Scholar
Abstract
An ideal codrug design should be able to control drug release, offer selectivity during drug delivery, and break down into non-toxic fragments after biodegradation. Our design incorporates d-ribofuranose as the core, with carbamate and carbonate groups as linking joints, a phosphodiester moiety as an enzyme recognition site, and lenalidomide and paclitaxel as the constituent drugs. The codrug synthesis involves seven steps with a 33% overall yield. The target codrug increases its water solubility 685 times versus paclitaxel.
Funding Information
  • Ministry of Science and Technology, Taiwan (110-2113-M-007-011, 110-2634-F-007-023)
  • Ministry of Education of Taiwan (109QR001I5, 110QR001I5)

This publication has 23 references indexed in Scilit: